Vitale Elsa, Rizzo Alessandro, Maistrello Lorenza, Nardulli Patrizia, Talienti Tiziana, Quaresmini Davide, De Summa Simona, Massafra Raffaella, Silvestris Nicola, Brunetti Oronzo
Department of Mental Health, Bari Local Health Authority, Scientific Directorate, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Front Oncol. 2024 Jul 18;14:1409132. doi: 10.3389/fonc.2024.1409132. eCollection 2024.
We performed a systematic review and meta-analysis to further explore the impact of the addition of immunotherapy to gemcitabine-cisplatin as first-line treatment for advanced biliary tract cancer (BTC) patients.
Literature research was performed, and hazard ratio values and 95% confidence intervals were calculated. Heterogeneity among studies was assessed using the tau-squared estimator . The total Cochrane Q test (Q) was also assessed. The overall survival rate, objective response rate, and progression-free survival in the selected studies were assessed.
A total of 1,754 participants were included. Heterogeneity among the studies selected was found to be non-significant (p = 0.78; tau = 0, I = 0%). The model estimation results and the forest plot suggested that the test for the overall effect was significant (Z = -3.51; p< 0.01).
The results of the current meta-analysis further confirm the role of immune checkpoint inhibitors plus gemcitabine-cisplatin as the new standard first-line treatment for advanced BTC patients.
https://www.crd.york.ac.uk/prospero, identifier CRD42023488095.
我们进行了一项系统评价和荟萃分析，以进一步探讨在吉西他滨-顺铂基础上加用免疫疗法作为晚期胆管癌（BTC）患者一线治疗的影响。
进行文献研究，并计算风险比数值和95%置信区间。使用tau平方估计量评估研究间的异质性。还评估了Cochrane总Q检验（Q）。评估所选研究中的总生存率、客观缓解率和无进展生存期。
共纳入1754名参与者。发现所选研究间的异质性不显著（p = 0.78；tau = 0，I = 0%）。模型估计结果和森林图表明总体效应检验具有显著性（Z = -3.51；p < 0.01）。
当前荟萃分析的结果进一步证实了免疫检查点抑制剂联合吉西他滨-顺铂作为晚期BTC患者新的一线标准治疗的作用。
